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CHAPTER 2
Considering the biology of late recurrences
in selecting patients for extended 
endocrine therapy in breast cancer




Extended endocrine therapy can reduce recurrences occurring more than 5 years after 
diagnosis (late recurrences) in estrogen receptor (ER)-positive breast cancer. Given 
the side effects of endocrine therapy, optimal patient selection for extended treatment 
is crucial. Enhanced understanding of late recurrence biology could optimize patient 
selection in this setting. We therefore summarized the current knowledge of late 
recurrence biology, clinical trials on extended endocrine therapy, and tools for predicting 
late recurrence and benefit from treatment extension. Extending 5 years of tamoxifen 
therapy with 5 years of tamoxifen or an aromatase inhibitor (AI) reduces late recurrence 
risk by 2–5%, but results of extending AI-based therapy are inconsistent. Although several 
clinicopathological parameters and multigene assays are prognostic for late recurrence, 
selection tools predicting benefit from extended endocrine therapy are sparse. Therefore, 
we additionally performed a pooled analysis using 2,231 mRNA profiles of patients with 
ER-positive/human epidermal growth factor receptor 2-negative breast cancer. Gene set 
enrichment analysis was applied on genes ranked according to their association with early 
and late recurrence risk. Higher expression of estrogen-responsive genes was associated 
with a high recurrence risk beyond 5 years after diagnosis when patients had received 
no systemic therapy. Although 5 years of endocrine therapy reduced this risk, this effect 
disappeared after treatment cessation. This suggests that late recurrences of tumors with 
high expression of estrogen-responsive genes are likely ER-driven. Long-term intervention 
in this pathway by means of extended endocrine therapy might reduce late recurrences in 
patients with tumors showing high expression of estrogen-responsive genes.
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INTRODUCTION
Endocrine therapy in patients with estrogen receptor (ER)-positive breast cancer has 
clearly improved patient outcomes. Nevertheless, at least 20–25% of patients experience 
breast cancer recurrence at some point, which might present as locoregional relapse, 
distant recurrence or second primary breast cancer.1,2 Half of these recurrences are late 
recurrences occurring more than 5 years after diagnosis.1 Even for patients with T1N0, 
ER-positive tumors who received 5 years of endocrine therapy, the cumulative distant 
recurrence rate 5–20 years after diagnosis is still 13%.2
Several trials have shown a reduced late recurrence risk with extended endocrine 
therapy beyond 5 years.3-7 However, absolute benefits of this extension are modest, yielding 
only a 2–5% reduction in late recurrence. As endocrine therapy can be accompanied by 
severe side effects, identification of patients who will benefit most from extended treatment 
is crucial. Multiple tools such as web-based risk calculators and multigene assays have 
been developed to estimate the recurrence risk in ER-positive breast cancer.8,9 Although 
some of these tools are also prognostic for late recurrence, not all patients with a high 
estimated risk will benefit from extended endocrine therapy.
Gaining insight into late recurrence biology could optimize patient selection 
for extended endocrine therapy. Therefore, we reviewed the current knowledge of late 
recurrence biology, clinical trials on extended endocrine therapy, and tools for predicting 
late recurrence and benefit from treatment extension. Additionally, we performed a 
pooled analysis using 2,231 mRNA profiles of primary ER-positive/human epidermal 
growth factor receptor 2 (HER2)-negative breast cancers to identify biological pathways 
associated with an increased early or late recurrence risk in patients that received no 
systemic treatment and in patients that only received 5 years of endocrine therapy.
CURRENT KNOWLEDGE OF LATE RECURRENCE BIOLOGY
Early distant recurrences, but not late recurrences, appear to be the result of a continuous-
growth model where the steps of the invasion-metastasis cascade are continuous.10 A 
retrospective study including 1,173 patients with breast cancer regardless of ER or HER2 
status, treated with mastectomy alone, showed a two-peak incidence: at 18 months 
and at around 60 months after surgery for local and distant recurrences.11 This two-
peak incidence, which was also observed in other studies, might be a result of tumor 
dormancy.12-16
Two types of tumor dormancy have been distinguished. In tumor mass dormancy, 
expansion of a micrometastatic lesion is inhibited as proliferating and dying tumor 
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cells balance each other. Underlying mechanisms for tumor mass dormancy include (i) 
angiogenic dormancy, where the size of the lesion is kept constant because of a limited blood 
supply, and (ii) immune-mediated dormancy, where a low number of proliferating tumor 
cells is maintained through a continuous cytotoxic activity.17 In cellular dormancy, single 
disseminated tumor cells (DTCs) reach a quiescent state by arresting in the G0-G1 cell 
cycle phase, which likely results from their inability to adapt to a new microenvironment 
after surviving dissemination.17,18
Knowledge of mechanisms responsible for the reactivation of dormant micrometastatic 
lesions or dormant DTCs is limited. This reactivation could be regulated mainly through 
signals from the tumor microenvironment, including cues in the extracellular matrix, the 
immune microenvironment and angiogenetic factors.17,19-21
EXTENDING TAMOXIFEN TREATMENT BEYOND 5 YEARS
All trials assessing extended endocrine therapy have been performed in patients regardless 
of HER2 status. Recurrences were defined as locoregional relapses, distant recurrences 
or second primary breast cancers. Disease-free survival (DFS) was defined as time from 
diagnosis to recurrence, second primary malignancy or death unless stated otherwise.
The first trials evaluating extended tamoxifen treatment included small numbers 
of patients with hormone receptor-positive and hormone receptor-negative tumors.22,23 
The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 trial was the 
first study to randomize 1,152 patients with ER-positive disease who completed 5 years 
of tamoxifen, to another 5 years of tamoxifen or placebo (Fig. 1).24 This study, which only 
included patients with node-negative disease, was terminated early after interim analyses 
indicated that a statistically significant benefit was unlikely.25 With a median follow-up of 
6.8 years, the 7-year DFS was 78% in patients receiving extended tamoxifen versus 82% in 
patients receiving placebo.
More recently, the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial 
randomized 6,846 patients with ER-positive disease who completed 5 years of tamoxifen 
to another 5 years of tamoxifen or no further treatment.3 With a median follow-up of 
7.6 years after randomization, a 3.7% difference was observed in the cumulative recurrence 
rate in years 5–14 after diagnosis in favor of the extended tamoxifen arm. Also, a 2.8% 
reduction in breast cancer mortality was seen in patients receiving 10 years of tamoxifen. 
Similar results were observed in the adjuvant Tamoxifen—To offer more? (aTTom) trial, 
which included 6,953 patients of which most had an unknown tumor ER status.4
Extended tamoxifen treatment seems to be reasonably tolerated. In ATLAS, 84% 
of patients who received extended tamoxifen and remained disease-free 2 years after 
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randomization were still on treatment. However, patients were preselected for good 
tamoxifen tolerance, so patient adherence to extended tamoxifen is likely somewhat 
lower than reported in ATLAS. It is known that 5 years of tamoxifen increases the risk for 
endometrial cancer and pulmonary embolism.26 In ATLAS, the incidence of endometrial 
cancer and pulmonary embolism approximately doubled when patients received extended 
tamoxifen. The cumulative endometrial cancer rate increased by 1.5% to 3.1% in years 
5–14 after diagnosis.
Based on the ATLAS and aTTom trials, current guidelines recommend that all 
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Figure. 1. Clinical trials on extending endocrine therapy beyond 5 years. Recurrences were defined as locoregional relapse, 
distant recurrence or second primary breast cancer. Median follow-up times were calculated from time of randomization onwards. 
The primary endpoint of each trial is displayed in bold. Relative risks and hazard ratios are presented with corresponding 95% 
confidence intervals. A relative risk or hazard ratio of greater than 1 represents a greater risk for the treatment arm (upper bar) 
compared to the control arm (lower bar) in each trial. *Breast cancer-specific death only. **Adapted median follow-up starting at 
3 years from randomization. ***Did not include primary malignancies. AI, aromatase inhibitor; Ana, anastrozole; ER, estrogen 
receptor; Exe, exemestane; FU, follow-up; HR, hazard ratio; Let, letrozole; LN, lymph node; NA, not available; Plac, placebo; RR, 




AROMATASE INHIBITOR-BASED TREATMENT AFTER 5 YEARS OF TAMOXIFEN
Trials evaluating extended treatment with aromatase inhibitors (AIs) have included only 
postmenopausal patients with hormone receptor-positive disease.
The MA.17 trial included 5,187 patients who completed 5 years of tamoxifen and 
randomized these patients to 5 years of letrozole or placebo (Fig. 1). This study was 
prematurely unblinded when interim analyses showed that letrozole reduced recurrence 
risk.28 A 4.6% lower 4-year recurrence rate was seen in patients receiving letrozole 
compared to placebo.5 Although no significant difference in overall survival (OS) was 
found initially, analysis adjusting for treatment crossover with a median follow-up of 
5.3 years revealed that letrozole prolonged OS (hazard ratio [HR] 0.61, 95% confidence 
interval [CI] 0.52–0.71).29 These findings resulted in the premature closure of the NSABP 
B-33 trial, where 1,598 patients after 5 years of tamoxifen were randomized to 5 years 
of exemestane or placebo.30 With a median follow-up of 2.5 years after randomization, 
a 2% difference was seen in the 4-year recurrence rate in favor of the exemestane arm. 
The Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 6a randomized 
856 patients who received 5 years of tamoxifen to 3 years of anastrozole or no further 
treatment.6 The cumulative recurrence rate 5 years after randomization was 12.2% for 
patients receiving no further treatment and 7.8% for patients receiving anastrozole. No 
significant difference in OS was observed.
Side effects of 5 years of AI-based treatment include arthralgia, hot flushes, 
cardiovascular disease and a decrease in bone mineral density resulting in osteoporosis 
or bone fractures.31-34 None of these trials reported an increased bone fracture incidence 
following extended treatment with an AI. MA.17 reported a 2.1% increase in newly 
diagnosed osteoporosis in patients receiving extended treatment. Hot flushes, arthralgia 
and myalgia were also more common. In NSABP B-33, 3% more grade 3 side effects, 
mainly arthralgia, fatigue and bone pain, were seen in patients receiving extended 
treatment. In ABCSG Trial 6a, 11.6% of patients receiving extended anastrozole withdrew 
prematurely because of adverse events.
Extending treatment with an AI after 5 years of tamoxifen reduces late recurrence 
risk, but is accompanied by an increase in side effects, mainly bone-related, and arthralgia. 
Current guidelines recommend that all postmenopausal patients who have received 
5 years of tamoxifen should be offered the option to extend treatment with 5 years of an 
AI.27
21
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EXTENDING AROMATASE INHIBITOR-BASED TREATMENT BEYOND 5 YEARS
The MA.17R trial included 1,918 patients who completed 5 years of letrozole, preceded in 
80% of patients by 5 years of tamoxifen (Fig. 1). Patients were randomized to letrozole for 
another 5 years or placebo.7 With a median follow-up of 6.3 years after randomization, 95% 
of patients who received letrozole were recurrence-free at 5 years versus 91% of patients 
who received placebo. This difference was mainly driven by a reduction in contralateral 
breast cancers (HR 0.42, 95% CI 0.22–0.81). In the NSABP B-42 trial, 3,966 patients who 
received an AI or tamoxifen followed by an AI for 5 years were randomized to 5 years of 
letrozole or placebo.35 As there was no significant difference in DFS, this trial did not meet 
its primary endpoint; the median follow-up was 6.9 years after randomization. Extended 
letrozole did result in a 3.3% lower 7-year recurrence rate and a 1.9% lower 7-year distant 
recurrence rate. The DATA trial randomized 1,912 patients who completed 2–3 years of 
tamoxifen to 3 or 6 years of anastrozole.36 Follow-up started 3 years after randomization. 
No significant difference in DFS was observed with a median follow-up of 4.2 years. 
However, post-hoc subset analysis showed that extended anastrozole improved DFS in 
patients with ER-positive/progesterone receptor (PR)-positive, node-positive disease (HR 
0.64, 95% CI 0.46–0.89), which was even more evident when patients also had a large 
tumor size (HR 0.53, 95% CI 0.35–0.82). Another trial evaluating the effect of 2–3 versus 
5 years of letrozole in patients who completed 2–3 years of tamoxifen is currently ongoing 
(NCT01064635).
Several trials compared different durations of extended AI-based treatment beyond 
5 years. In the Investigation on the Duration of Extended Adjuvant Letrozole treatment 
(IDEAL) trial, after 5 years of any endocrine therapy 1,824 patients were randomized to 
2.5 or 5 years of letrozole.37 No significant difference in DFS, in which second primary 
malignancies were not considered events, was observed with a median follow-up of 
6.6 years after randomization. However, 5 years of letrozole did result in a reduction 
of second primary breast cancers (HR 0.39, 95% CI 0.19–0.81). The ABCSG-16 trial 
randomized 3,469 patients after 5 years of any endocrine therapy to 2 or 5 years of 
anastrozole.38 With a median follow-up of 8.9 years after randomization, no significant 
difference was found in DFS or OS. Finally, the Study of Letrozole Extension (SOLE) 
trial randomized 4,884 patients with node-positive disease after 5 years of any endocrine 
therapy to 5 years of continuous or intermittent letrozole.39 With a median follow-up of 
5 years after randomization, no significant difference was observed in DFS or OS.
In the MA.17R trial, the incidences of new-onset osteoporosis and bone fractures were 
both 5% higher in patients receiving extended letrozole. In contrast, NSABP B-42 and 
DATA did not report a significant difference in bone fractures. In DATA, an increased 
22
CHAPTER 2
incidence of arthralgia and myalgia was seen in patients receiving extended treatment, 
of which 24% withdrew because of side effects. Furthermore, a meta-analysis of seven 
clinical trials comprising 16,349 patients showed that extended AI treatment after 5 years 
of either tamoxifen or AI-based therapy results in an increased risk for cardiovascular 
disease and fractures.40 As patients were preselected for good tolerance of endocrine 
therapy, these data indicate that treatment extension itself does inflict additional toxicity. 
In both IDEAL and ABCSG-16, around 60% of patients receiving 5 years of extended 
treatment completed treatment.
In summary, no evidence currently indicates that extending AI-based treatment 
beyond 5 years reduces late recurrence risk in an unselected population of patients 
with ER-positive breast cancer. Subset analyses indicate that patients with ER-positive/
PR-positive, node-positive disease might benefit from extended AI-based treatment. 
However, these assumptions need to be interpreted with caution as the number of events 
in these analyses were low.
TOOLS FOR PREDICTING LATE RECURRENCE AND BENEFIT FROM EXTENDED 
ENDOCRINE THERAPY
Several tools that are currently used to predict recurrence risk in ER-positive breast 
cancer also have prognostic value for late recurrence. A meta-analysis including 62,923 
patients showed that T and N status were the strongest determinants for late distant 
recurrence after 5 years of endocrine therapy.2 This has also been demonstrated by several 
smaller studies.41,42 Web-based risk calculators such as Adjuvant!Online, PREDICT and 
CancerMath also provide information on long-term recurrence risk by incorporating 
clinicopathological parameters and epidemiological data (Table 1).8,43,44
Multigene assays have also been assessed in the context of late recurrence (Table 2). 
Oncotype DX is a 21-gene assay measured at mRNA level that identifies patients with 
early-stage, node-negative disease who are likely to benefit from adjuvant chemotherapy.9 
Prosigna is a mRNA-based 50-gene assay incorporating genes from the PAM50 algorithm 
for intrinsic subtype classification; it estimates the 10-year distant recurrence risk.45,46 
IHC4 is a prognostic score derived from immunohistochemical staining levels of ER, PR, 
HER2 and Ki67.47 The Breast Cancer Index combines two independent mRNA biomarkers, 
HOXB13/IL17BR (H/I) and the Molecular Grade Index, to calculate distant recurrence 
risk in patients with node-negative disease.48,49 Finally, EndoPredict is a RNA-based 11-
gene assay composed of proliferative and ER-related genes, which can be combined with 
tumor size and nodal status, resulting in the EPclin score.50 In several patient subsets of the 
TransATAC trial, where patients with ER-positive disease received 5 years of endocrine 
therapy, Prosigna, Breast Cancer Index and EndoPredict/EPclin predicted late distant 
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Table 1. Web-based tools for long-term risk in estrogen receptor-positive breast cancer.
Web-based tool Assessment Conceptual basis Required information Utility
Adjuvant!Online Risk of recurrence 
and death at 10 years
Estimated of prognosis based 
on SEER data and estimated of 
efficacy of adjuvant therapy based 
on EBCTCG data
Patient age at diagnosis, patient 
comorbidities, tumor size, ER 
status and number of lymph 
nodes involved
Estimate realistic 
benefit of adjuvant 
therapy
PREDICT 5-year and 10-year 
survival risk
Data from East Anglia Cancer 
Registration and Information 
Center 
Patient age at diagnosis, mode 
of detection, tumor size, tumor 
grade, ER status, HER2 status, 
Ki67 status, chemotherapy 
regimen
Estimate the effect 
of endocrine therapy 
and chemotherapy
CancerMath 15-year mortality 
risk
SNAP (size, nodes, prognostic 
markers) for integrating 
prognostic factors to estimate 
mortality risk NIH population 
data to estimate the risk of non-
breast cancer death
Patient age at diagnosis, tumor 
size, number of lymph nodes 
involved, ER status, PR status, 
HER2 status, histological type, 
grade, treatment regimen
Estimate 15-year 
mortality risk and 
impact of endocrine 
therapy and 
chemotherapy 
EBCTCG, Early Breast Cancer Trialists’ Collaborative Group; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; NIH, 
National Institutes of Health; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.
Table 2. Multigene assays evaluated to predict late recurrence risk in estrogen receptor-positive breast cancer.
Assay Details Technology Application Output




Prediction of 10-year recurrence 
risk in patients with ER+/HER2-, 
LN- breast cancer
Continuous recurrence 
score & risk classification 
(low, intermediate, high)
Prosigna45,46 50 genes used in the 
PAM50 algorithm for 




Prediction of 10-year recurrence 
risk in patients with ER+/HER2-, 
LN+/LN- breast cancer
Continuous recurrence 
score & risk classification 
(low, intermediate, high)
IHC447 IHC staining levels of ER, 
PR, HER2 and Ki67
IHC Prediction of recurrence risk in 
patients with ER+/HER2- breast 
cancer
Continuous recurrence 









Prediction of recurrence risk in 
patients with ER+/HER2-, LN- 
breast cancer
Risk classification (low, 
high) 




Prediction of recurrence risk in 
patients with ER+/HER2-, LN+/
LN- breast cancer
Risk classification (low, 
high) 
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; LN, lymph node; mRNA, messenger 
ribonucleic acid; RT-PCR, reverse transcription polymerase chain reaction.
recurrence risk independent of age, tumor size, grade, nodal status and treatment (Table 
3). In contrast, Oncotype DX and IHC4 were of little or no prognostic value.42,51,52 In a 
comparison of all assays in 689 patients from TransATAC, Prosigna was the strongest 
independent predictor for late recurrence in node-negative breast cancer, while EPclin 
was the strongest in patients with node-positive disease.53 The independent prognostic 
value for late distant recurrence of Prosigna, Breast Cancer Index and EndoPredict has 
also been demonstrated in other patient cohorts.54-58
ER-related gene expression has also been studied in the context of late recurrence. 
A study including 1,242 patients with ER-positive breast cancer treated with 5 years of 
tamoxifen showed that, independent of age, T stage, nodal status, grade and HER2 status, 
tumors with a combined high proliferation and high ER-related score had the greatest 
increase in distant recurrence risk after 5 years of tamoxifen.59 Also, among patients with 
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Table 3. Studies assessing the prognostic value of multigene assays for late recurrence independent from clinicopathological 
parameters.
Study Population Assay Prognostic value for late recurrence P
Sestak et al.42 TransATAC trial
n = 940
ER+, LN+ and LN-
Postmenopausal




LR χ2 = 16.29
LR χ2 = 5.55












LR χ2 = 7.97
LR χ2 = 0.48




Buus et al.52 TransATAC trial
n = 820
HR+/HER2-, LN+ and LN-
Postmenopausal




LR χ2 = 9.8
LR χ2 = 9.9














LR χ2 = 3.3
LR χ2 = 11.2*
LR χ2 = 1.9
LR χ2 = 18.4*
















LR χ2 = 0.8
LR χ2 = 4.6*
LR χ2 = 0.7
LR χ2 = 3.3






Filipits et al.54 ABCSG-8
n = 1,246
HR+, LN+ and LN-
Postmenopausal
5 years of ET
Prosigna LR χ2 = 15.3 < 0.001
Sestak et al.55 ABCSG-8 / TransATAC
n = 2,137
HR+, LN+ and LN-
Postmenopausal
5 years of ET
Prosigna HR 2.07 (95% CI 1.63 to 2.64) < 0.001











Breast Cancer Index HR 9.24 (95% CI 2.85 to 30.00) < 0.001
Dubsky et al.57 ABCSG-6 / ABCSG-8
n = 1,702
ER+/HER2-, LN+ and LN-
Postmenopausal
5 years of ET
Endopredict HR 1.28 (95% CI 1.10 to 1.48) 0.001
Zhang et al.58 Massachusetts General Hospital 
cohort
n = 402
HR+, LN+ (1-3 nodes)
Pre and postmenopausal
ET +/- chemotherapy
Breast Cancer Index (with 
tumor size and grade)
HR 1.41 (95% CI 1.06 to 1.89) 0.02
CI, confidence interval; ER, estrogen receptor; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; HR+, 
hormone receptor-positive; LN, lymph node; LR, likelihood ratio. *P < 0.05.
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highly proliferative tumors treated with neoadjuvant letrozole, a 100% (11/11) clinical 
response rate was seen in tumors with high ER-related gene expression, compared to 47% 
(7/15) in case of low ER-related gene expression. In 1,125 patients who received 5 years 
of endocrine therapy in TransATAC, tumors with low ESR1 mRNA expression showed a 
steady distant recurrence rate across 10 years after diagnosis, while high ESR1 expression 
was associated with a lower early distant recurrence risk but an increased late distant 
recurrence risk.60 Furthermore, Oncotype DX was prognostic for late distant recurrence 
in case of high tumor ESR1 mRNA expression in chemotherapy and tamoxifen-treated 
patients and patients treated with tamoxifen only, while this was not the case for low ESR1 
expression.61
Recently, the Clinical Treatment Score post-5 years (CTS5) was developed specifically 
to predict late distant recurrences by incorporating nodal status, tumor size, grade and age 
into a continuous score.62 The CTS5 was developed in the ATAC trial and validated in the 
BIG 1-98 study, where postmenopausal patients received 5 years of endocrine therapy. 
The distant recurrence risk in years 5–10 was 3.0% for low-risk patients, 7.3% for those 
with intermediate risk, and 18.9% for high-risk patients.
Although several clinicopathological parameters and multigene assays are prognostic 
for late recurrence, this does not imply that patients with a high estimated risk will benefit 
from extended endocrine therapy. Only the Breast Cancer Index has been investigated 
in this context. In a cohort of 249 patients participating in the MA.17R trial, the distant 
recurrence rate was 16.5% lower in patients with high H/I-expressing tumors treated with 
extended letrozole compared to placebo.63 However, thus far the predictive value of the 
Breast Cancer Index has not been validated. Current guidelines do not recommend the 
use of multigene assays in the decision-making on extended endocrine therapy.64,65
HIGHER EXPRESSION OF ESTROGEN-RESPONSIVE GENES IS ASSOCIATED WITH A 
HIGHER RISK OF LATE RECURRENCE
More insight into late recurrence biology could improve patient selection for extended 
endocrine therapy. Therefore, we performed a retrospective pooled analysis to gain 
insight into biological pathways associated with an increased early or late recurrence 
risk. We collected publicly available mRNA profiles of 2,231 primary ER-positive/
HER2-negative breast tumors as previously described.66 Patient characteristics are 
provided in Supplementary Table 1. Associations with early recurrence were studied in 
all patients with censoring at 5 years if no event occurred <5 years after diagnosis. To 
study associations with late recurrence, we defined a second set that contained patients 














Figure 2. Definition of early and late 
recurrence patient sets. For the early 
recurrence set, patients with a follow-up 
≥5 years were censored at 5 years. For the 
late recurrence set, patients with a follow-up 
<5 years were excluded. For each set, univariate 
and multivariate Cox regression analysis was 
performed to assess associations of individual 
gene expression with recurrence-free survival. 
Next, genes were ranked according to their 
association with recurrence-free survival and 
Gene Set Enrichment Analysis was performed 
on the ranked gene lists.
Set I = early recurrence set



















































































































































































Figure 3. Gene set enrichment analysis in early and late recurrence patient sets. Gene set enrichment analysis was performed 
on ranked gene lists based on their association with recurrence-free survival. A green triangle indicates that higher expression 
of genes in a gene set was associated with a lower risk for recurrence. A blue triangle indicates that higher expression of genes 
in a gene set was associated with higher risk for recurrence. The size of the triangle represents the normalized enrichment score 
(NES). The insert shows the NES scores for the gene set ‘estrogen response late’ for the risk of early and late recurrence in patients 
who had received 5 years of endocrine therapy only and patients who had received no systemic treatment. ET, endocrine therapy. 
*Contains estrogen-responsive genes that were identified by comparing gene expression in estradiol-treated and untreated 
estrogen receptor-positive breast cancer cell lines.
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genes according to their association with recurrence-free survival, defined as time of 
diagnosis to local recurrence or distant metastasis, as determined with Cox regression 
analysis. Next, we performed gene set enrichment analysis with the Hallmark collection 
from the Molecular Signatures Database.67 A positive normalized enrichment score (NES) 
represented an association between higher expression of genes in a gene set with a lower 
recurrence risk. A negative NES represented an association of higher expression of genes 
in a gene set with an increased recurrence risk. Methods are described in more detail 
in Supplementary Methods. Results of the Cox regression analysis of individual gene 
expression with recurrence-free survival are provided in Supplementary File 1. NESs for 
all Hallmark gene sets are provided in Supplementary File 2.
In all patients, the largest shift in the association for early recurrence and late 
recurrence was observed for the ‘estrogen response late’ gene set. This gene set contains 
estrogen-responsive genes that were identified by comparing gene expression in estradiol-
treated and untreated ER-positive breast cancer cell lines. Higher expression of these 
estrogen-responsive genes was associated with a lower early recurrence risk (NES = 1.89), 
but an increased late recurrence risk (NES = −4.79).
When we corrected for age, grade, tumor size, nodal status and systemic treatment, 
in all patients, higher expression of genes in the ‘estrogen response late’ gene set remained 
associated with a lower early recurrence risk (NES = 2.23) and a higher late recurrence 
risk (NES = −3.47) (Fig. 3). In patients who had not received any systemic treatment 
(i.e. no chemotherapy or endocrine therapy, n = 497), higher expression of genes in 
the ‘estrogen response late’ gene set was associated with an increased early recurrence 
risk (NES = −1.06), although not significantly, and an increased late recurrence risk 
(NES = −1.90). In contrast, in patients who had received 5 years of endocrine therapy only 
(n = 591), higher expression of these genes was associated with a lower early recurrence 
risk (NES = 1.58), while it remained associated with an increased late recurrence risk 
(NES = −2.72).
This pooled analysis shows that patients with higher expression of estrogen-
responsive genes in the primary tumor who did not receive systemic treatment had a high 
recurrence risk persisting beyond 5 years. While 5 years of endocrine therapy reduced the 
risk for early recurrence in these patients, the late recurrence risk remained. This indicates 
that patients with higher expression of estrogen-responsive genes might benefit from 
extended endocrine therapy.
DISCUSSION
Our review of clinical trials on extended endocrine therapy shows that the benefit of 
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extended therapy on late recurrence is small. Although several tools are prognostic for 
late recurrence, selection tools for benefit from extended endocrine therapy are sparse. 
In clinical practice, patient selection for extended endocrine therapy therefore remains 
problematic.
Our pooled analysis suggests that late recurrences of tumors with high expression of 
estrogen-responsive genes are likely ER-driven. Long-term intervention in this pathway 
with extended endocrine therapy might reduce late recurrences in patients with these 
breast cancers. Previously, it was shown that patients with highly proliferative tumors and 
high ER-related gene expression had an increased risk for late recurrence.59 ER-related 
gene expression alone was only assessed in univariate analysis, which revealed that high 
expression was associated with a low early distant recurrence risk, and no association 
was found with late distant recurrence in patients who received 5 years of tamoxifen and 
patients who received no systemic treatment. This is in contrast to our pooled analysis and 
might be explained by the fact that we corrected for relevant clinicopathological variables. 
Also, we only included patients with HER2-negative disease. Other studies have shown an 
increased risk for late recurrence in patients with tumors showing high ER-related gene 
expression who were treated with 5 years of endocrine therapy but it remained unknown 
whether this risk could be reduced by extended endocrine therapy.60,61 Our pooled 
analysis showed that patients with higher expression of estrogen-responsive genes have 
increased late recurrence risk and, importantly, that this increased risk might be reduced 
by extending endocrine therapy.
Although extended endocrine therapy beyond 5 years reduces late recurrence risk 
in some patients, others still relapse. For these patients, alternative treatment approaches 
are warranted. In this context, several clinical trials are currently assessing the effect of 
combining endocrine therapy with CDK-inhibitors (NCT03078751, NCT02513394, 
NCT03081234) or mTOR-inhibitors (NCT01674140). Other potential strategies include 
developing agents capable of eradicating dormant DTCs or finding ways to keep these cells 
in a dormant state indefinitely. However, no actionable targets have yet been identified.68
In conclusion, extending endocrine therapy to reduce late recurrence risk in patients 
with ER-positive breast cancer seems to benefit only a subset of patients. Identification 
of these patients remains a challenge given the few predictive biomarkers for extended 
endocrine therapy. We show that patients with higher expression of estrogen-responsive 
genes in the primary tumor have an increased late recurrence risk and that these patients 
might benefit most from extended endocrine therapy.
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Supplementary Table 1. Baseline patient characteristics
No. (%) Valid %
Age at diagnosis (years)
   ≤ 50
   > 50







   T0
   T1
   T2
   T3
   T4













   Positive
   Negative







   1
   2
   3









   Chemotherapy
   Hormonal therapy for 5 years
   Hormonal therapy for unknown duration
   Hormonal therapy & chemotherapy
   No systemic treatment













Data acquisition and clinicopathological data collection
A detailed description of the data collection has been previously described.1 In short, 
publicly available raw gene expression data from primary breast cancer samples generated 
with Affymetrix HG-U133A or Affymetrix HG-U133 Plus 2.0 was collected from the Gene 
Expression Omnibus (platforms GPL96 and GPL570).2 Samples were searched using the 
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following keywords: ‘breast’, ‘TNBC’, ‘HER2’, ‘estrogen’, ‘progesterone’, ‘HER-2’, ‘mamma’, 
‘ERBB2’, and ‘HER2/neu’. Samples were removed in case they represented cell line or 
metastasized material, or in case patients were treated before biopsy. Non-corrupted raw 
CEL files were downloaded for the remaining samples. An MD5 hash for Affymetrix 
data was generated for each CEL file, after which duplicate samples could be identified 
and removed.  We used the robust multi-array average algorithm for preprocessing and 
aggregation of the raw expression data. Principal component analysis was used for quality 
control of the remaining expression data as previously described.3–5
Clinicopathological data and information and treatment and survival were collected 
for the remaining samples whenever available. Whenever data on ER and HER2 status was 
missing, we inferred these using regular mRNA expression levels of ER (Affymetrix probe 
205255_at) and functional genomic mRNA5 expression levels of HER2 (Affymetrix probe 
216836_s_at). Only samples from patients with ER-positive/HER2-negative breast cancer 
with information available on recurrence-free survival (RFS), defined as time of diagnosis 
to time of local or distant recurrence, were used for further analysis (n = 2,231). 
Associations of individual gene expression levels with early and late recurrence risk
To study differences in the underlying biology of early and late recurrences, we defined 
two patient sets. To study associations with early recurrence, we defined a set including 
all patients with censoring at 5 years if no event occurred <5 years after diagnosis (n = 
2,231). To study associations with late recurrence, we defined a second set that contained 
patients with a follow-up ≥5 years and no event <5 years after diagnosis (n = 1,446). For 
each set, associations of individual gene expression with recurrence risk were assessed 
through univariate and multivariate Cox regression analysis. For multivariate analysis, 
age, tumor, size, tumor grade, lymph node involvement and treatment regimen were 
included as covariates. 
 
Gene set enrichment analysis
For the early and late recurrence patient sets separately, all genes were ranked according 
to their association with RFS. Genes were ranked in such a way that the gene having the 
most significant association with a higher recurrence risk was given the lowest rank (i.e. 
rank 1). The gene having the most significant association with a lower recurrence risk was 
given the highest rank (i.e. rank 22,777). Next, gene set enrichment analysis was applied 
on these ranked gene lists using the Hallmark collection from the Molecular Signatures 
Database.6 Here, a positive NES would indicate an association between higher expression 
of genes in a gene set with a lower recurrence risk. A negative NES would indicate an 
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